Simufilam (original) (raw)

Simufilam is an Investigational New Drug for the treatment of Alzheimer's disease in phase III clinical trials expected to finish in 2023 or 2024. It is being developed by the American pharmaceutical firm Cassava Sciences. The US Food and Drug Administration received a citizen petition in August 2021 to stop the clinical trials. Other scientists have also questioned the preclinical results, citing the small sample size, alleged methodological flaws in an in vitro technique, alleged manipulations of western blot images and potential conflict of interest.